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Abstract
Ephrin-B2 is predominately expressed in endothelium of arterial origin, involved in developmental angiogenesis and
neovasculature formation through its interaction with EphB4. Despite its importance in physiology and pathological
conditions, it has been challenging to produce monoclonal antibodies against ephrin-B2 due to its high conservation in
sequence throughout human and rodents. Using a novel approach for antibody selection by panning a phage library of
human antibody against antigens displayed in yeast, we have isolated high affinity antibodies against ephrin-B2. The
function of one high affinity binder (named as ‘EC8’) was manifested in its ability to inhibit ephrin-B2 interaction with EphB4,
to cross-react with murine ephrin-B2, and to induce internalization into ephrin-B2 expressing cells. EC8 was also compatible
with immunoprecipitation and detection of ephrin-B2 expression in the tissue after standard chemical fixation procedure.
Consistent with previous reports on ephrin-B2 induction in some epithelial tumors and tumor-associated vasculatures, EC8
specifically detected ephrin-B2 in tumors as well as the vasculature within and outside of the tumors. We envision that
monoclonal antibody developed in this study may be used as a reagent to probe ephrin-B2 distribution in normal as well as
in pathological conditions and to antagonize ephrin-B2 interaction with EphB4 for basic science and therapeutic
applications.
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Introduction
The erythropoietin-producing hepatocellular (Eph) receptors
and their ligands, ephrins comprise the largest subfamily of
receptor tyrosine kinases (RTK), playing an important role in
physiology such as embryogenesis, organ development, and
angiogenesis as well as implicated in several types of cancers [1].
Among different classes of ephrins, ephrin-B2 is primarily
expressed in arterial endothelial cells and neovasculature, forming
a bidirectional signal with its cognate receptor EphB4, which is
mainly expressed in venous endothelial cell [2,3]. The importance
of such interaction in a developmental process has been
demonstrated by impaired angiogenesis and ultimately embryonic
lethality in mice due to homozygous mutation of ephrin-B2 or
EphB4 [3,4,5,6]. The role of EphB4 and ephrin-B2 also extends to
tumor growth and angiogenesis [1,7]. Inhibition of their
interaction by EphB4 antibody or extracellular fragment of
EphB4 can inhibit tumor angiogenesis and tumor growth
[8,9,10]. Ephrin-B2 is involved in vascular endothelial growth
factor (VEGF) signaling, through the internalization of VEGF
receptor in all endothelial cell types during physiological and
pathological angiogenesis [11,12,13], and could be upregulated in
VEGF-treated endothelial cells [5,6]. Expression of ephrin-B2
along with EphB4 was found to be higher in many tumors
including colorectal, breast, ovarian, and lung, serving as a poor
prognostic marker [14,15,16,17,18].
Despite the importance of ephrin-B2 in physiology and
pathological conditions, there are no widely available monoclonal
antibodies against ephrin-B2, likely attributed to the fact that
immume system in rodents prevents responses to self antigen or to
highly conserved human antigens. To overcome the problem with
generating antibodies against highly conserved antigens, mice with
impaired immune tolerance (e.g. NZB/W) have been exploited
[19,20]; however, concerns remain on this alternative approach
due to the observations of multi-specificity and low-affinity on
auto-antibodies developed from autoimmune mice [20]. In order
to generate antibodies against highly conserved ephrin-B2, we
used phage display of single chain human antibody and screened
them against ephrin-B2 expressed in yeast. From our previous
work [21], we found that phage panning against antigens
displayed in yeast is highly efficient in rapid enrichment of specific
phage clones, obviating the need to produce soluble antigens as
well as ensuring native conformation. With newly developed
monoclonal antibody, we found that tumors of colon, breast,
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normal tissues. Antibody staining was also observed in the
neovasculature within the tumor, corresponding to new vessel
sprouts. Our antibody also exhibited properties such as its ability
to cross-react with murine ephrin-B2, to inhibit EphB4 binding,
and to be internalized into cells after binding to ephrin-B2. We
anticipate that antibodies developed in this study will be useful in
probing ephrin-B2 distribution in normal and disease processes,
and in antagonizing the interaction between ephrin-B2 and EphB4
for scientific and therapeutic applications.
Results
Novel strategy of selecting antibodies against ephrin-B2
We have previously shown that phage library of human
antibody can be directly panned against antigens expressed in
yeast (Fig. 1A) with great efficiency in selection of high affinity
monoclonal antibodies [21]. Surface expression of ectodomain of
ephrin-B2 on yeast cell surface was first validated by antibody
binding to Myc tag, which was placed at the C-terminal of ephrin-
B2, as well as the binding of EphB4, a physiological receptor of
ephrin-B2 (Fig. 1A&B). Subtractive panning of a phage library of
human single chain fragment variable fragment (scFv), consisting
of depletion against yeast expressing irrelevant antigens followed
by positive selection against ephrin-B2, resulted in a progressive
increase in the percentage of phage clones bound to ephrin-B2
(Fig. 1B). A total of 96 phage clones were selected from the third
round pool and tested individually for binding to ephrin-B2 using
flow cytometry. This resulted in 85 clones with positive binding
(data not shown). Out of these 85 clones, 10 high-affinity phage
clones were then sequenced, which identified three unique clones
(designated as scFv-EA6, scFv-EB1 and scFv-EC8). Two best
binders, scFv-EB1 and scFv-EC8 were chosen for production in
bacteria and purified by nickel-nitrilotriacetic acid (Ni-NTA)
column, followed by gel filtration chromatography, which resulted
in one distinct band around 35 kDa in SDS-PAGE (Fig. 1C).
Soluble scFv-EB1 and scFv-EC8 not only retained binding to yeast
but also showed specific binding to ephrin-B2 expressed in
mammalian cells, judging from the detection of basal expression in
293T and enhanced binding after transient expression of full-
length ephrin-B2 in 293T (Fig. 1D). scFv-EA6, scFv-EB1 and
scFv-EC8 differed mainly within the complementarity determining
regions (Fig. 1E). Overall, scFv-EC8 showed highest binding
affinity to ephrin-B2, and was chosen for further studies.
Characterization of single-chain antibody fused to Fc
domain
Although scFv-EC8 was fully functional in binding to ephrin-
B2, for future in vivo applications and many standard assays relying
on the presence of immunoglobulin Fc region, scFv fusion to Fc
was constructed in pcDNA3.1 and produced in mammalian cells
(Fig. 2A). Under the reducing condition, the Fc fusion of scFV-
EC8 migrated around 64 kDa, consistent with its nominal
molecular weight. scFv-EC8 fusion to Fc (designated as EC8)
was fully functional, retaining specific binding to ephrin-B2
expressed in yeast and in 293T (Fig. 2B) with higher level of
Figure 1. Selection, validation, and sequence of ephrin-B2-specific human single-chain antibodies. (A) A schematic diagram of phage
panning against antigens expressed in yeast display system [34]. (B) Immunofluorescence flow cytometry measurements of protein and phage
binding to yeast cells. Surface-displayed ephrin-B2 was detected by the binding of anti-Myc antibody (‘Myc’) as well as recombinant human EphB4-Fc
(‘EphB4’) to yeast cells (top panel). Progressive enrichment of phage clones from first three rounds of panning (denoted as ‘1 st’, ‘2 nd’ and ‘3 rd’) was
detected by antibody against His tag (bottom panel). Histograms drawn in shaded area and solid lines indicate antibody binding to uninduced and
induced yeast cells, respectively. The percentage of phage clones with positive binding is indicated. (C) SDS-PAGE of scFv-EB1 (lane ‘1’) and scFv-EC8
(lane ‘2’). (D) Ephrin-B2 specific scFv binding to irrelevant yeast cells, yeast cells with expression of ephrin-B2 ectodomain, 293T cells, and 293T cells
with transient expression of full-length ephrin-B2. Shown are the histograms of cells labeled with secondary antibody with (solid line) and without
(shaded area) ephrin-B2 specific scFv as primary antibody. (E) Sequence alignment of scFv-EA6, scFv-EB1, and scFv-EC8. Complementarity
determining regions (CDR), the beginning of immunoglobulin variable heavy (VH) and variable light (VL) chain domains, and the linker connecting VH
and VL are noted. * indicates amino acids differ between scFvs.
doi:10.1371/journal.pone.0030680.g001
Conformation-Specific mAb against Ephrin-B2
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30680binding compared with the levels seen with scFv-EC8 (Fig. 1D).
EC8 also exhibited comparable binding to murine ephrin-B2
expressed in transformed murine ovarian cells [22] (Fig. 2B), an
anticipated result due to the fact that murine ephrin-B2 differed by
only three residues from human ephrin-B2 expressed in yeast
(Thr-22 to Gly-165) for phage screening. The binding affinity
(equilibrium dissociation constant, KD) of EC8 to ephrin-B2 was
around 3.2 nM, based on the fluorescence measurement using
ephrin-B2-expressing 293T cells labeled in serial dilutions of EC8
(Fig. 2C). The increase in affinity of EC8 to ephrin-B2 was due to
the dimerization effect of scFv, commonly noted as bivalency or
avidity effect.
EC8 was conformation-specific against ephrin-B2, indicated
from significant loss of binding to ephrin-B2 expressing yeast cells
when ephrin-B2 was partially denatured by incubating cells either
in guanidine hydrochloride at 6 M or in elevated temperature
(Fig. 2D). The reduction in the level of EC8 binding to ephrin-B2
was not due to a change in surface expression as antibody binding
to Myc tag was invariant. The property of EC8 to recognize
conformation-specific epitope was also corroborated by its inability
to stain ephrin-B2 in western blot (data not shown). We then tested
if EC8 would specifically pull down ephrin-B2 from detergent-
solubilized 293T cell lysates. Conformation-specificity of mono-
clonal antibody (mAb) EC8 was also confirmed with the detection
of one distinct band of ,45 kDa in size from the lysates only after
precipitation with EC8, stained by polyclonal antibody against
ephrin-B2 (Fig. 2E). Due to high sequence homology among some
members of ephrin family, polyclonal antibodies against ephrin-B2
often crossreact with other ephrins like ephrin-B1 and ephrin-A5,
which share sequence identity at 43% and 41% with ephrin-B2,
Figure 2. Conversion of scFv-EC8 as a fusion to immunoglobulin Fc and functional test. (A) SDS-PAGE images of EC8 resolved under
reducing (R) and non-reducing (NR) conditions. (B) EC8 (solid line) binding to yeast cells, 293T with stable expression of ephrin-B2, and murine ovarian
epithelium. The binding of isotype control is shown in shaded area. (C) Flow cytometry measurements of EC8 binding to 293T cells are shown in filled
squares. First order Langmuir adsorption model was used to fit the data to estimate equilibrium dissociation constant (KD). (D) Conformation
speficifity of EC8 against eprhin-B2 was examined by flow cytometry with (‘+’) or without (‘2’) incubating cells either in 6 M guanidine
hydrocholoride (‘GnHCl’) for 20 min or in elevated temperature at 80uC (‘Heat’) for 10 min. (E) Western blot image of immunoprecipitated ephrin-B2
from 293T cells with (‘+’) or without (‘2’) EC8 antibody, detected by rabbit ephrin-B2 polyclonal antibody. (F) Flow cytometry measurements of EC8
binding to ephrin-B1 and ephrin-A5 displayed on yeast. Labeling of uninduced yeast cells is shown in shaded histograms. (G&H) Competition assay.
Relative binding of EphB4 (100 nM) to yeast cells expressing ephrin-B2, preincubated with varying concentrations of EC8, was measured by flow
cytometry. Affinity purified human IgG was included as isotype control. n=3 independent measurements. (I) Confocal microscopic images of surface-
bound EC8 and internalized ones before and after membrane permeabilization of 293T cells. Scale bar=10 mm.
doi:10.1371/journal.pone.0030680.g002
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ephrins tested, EC8 was found specific to ephrin-B2 with little
binding to ephrin-B1 and ephrin-A5 (Fig. 2F).
mAb EC8 blocked ephrin-B2 interaction with EphB4 and
was internalized by ephrin-B2 ligation
After confirming specific binding of EC8 to ephrin-B2, we
examined if EC8 was able to block ephrin-B2 interaction with its
cognate receptor, EphB4. This would potentially be useful in
blocking bidirectional signals triggered by ephrin-B2 and EphB4
interaction, which is important for normal physiology as well as in
disease progression. In comparison to human immunoglobulin G
(IgG) as isotype control, increasing concentration of EC8 added to
yeast cells expressing eprhin-B2 led to a gradual decrease in the
binding of EphB4 (used at 100 nM) to ephrin-B2, close to
complete inhibition seen at 250 nM of EC8 (Fig. 2G&H). We
detected the distribution of EC8 in 293T after labeling under
fluorescence microscope, and observed that ephrin-B2 ligation by
EC8 triggered cells to internalize the antibody. In order to
differentiate surface-bound vs. intracellular pool of EC8, confocal
microscopy was used to image cells prior to and after membrane
permeabilization, which visualized distinct intracellular staining of
EC8 (Fig. 2I).
EC8 detection of ephrin-B2 expression in tumor tissues
and tumor-associated vasculature
Upregulation of ephrin-B2/EphB4 has been observed in many
tumors, including ovary, colon, breast, and glioma, with a strong
correlation with poor prognosis [14,15,16,17,18,23,24]. With two
widely used colon cancer cell lines, COLO205 and HCT116, we
found upregulation of ephrin-B2 by flow cytometry using EC8
(Fig. 3A). Chinese hamster ovarian (CHO) cells with no ephrin-B2
expression were included as a negative control. The relative levels
of eprhin-B2 between different cell lines were further confirmed by
RT-PCR, with 293T cells stably expressing ephrin-B2 as a positive
control (Fig. 3B). Since not all conformation-specific antibodies are
compatible with immunohistology after a standard procedure for
tissue fixation, we examined if EC8 can be used to probe eprhin-
B2 expression in the tissue. When colon tumor tissues were
immunostained after tumor growth in mice and harvest, EC8 not
only delineated human tumor xenograft with high ephrin-B2
expression, but also identified the vasculature within the tumor
due to the cross-reactivity of EC8 with both human and murine
ephrin-B2 (Fig. 3C). EC8 staining of ephrin-B2 clearly differen-
tiated tumor cells (marked with arrowhead) from the murine
stroma (marked with arrow) (Fig. 3C).
EC8 detection of the upregulation of ephrin-B2 in diverse
human tumors of epithelial origin
We further examined if EC8 could be applied to detect ephrin-
B2 expression in other types of tumor directly collected from
human patients. Among several epithelium-originated cancers,
ranging from ovarian, lung, prostate, breast to colon, high level
expression of ephrin-B2 was all found by immunostaining
(Fig. 4A&B). In comparison to normal tissues or tumor stroma
showing no or only baseline ephrin-B2 staining, malignant tumor
cells characterized by their irregular cell shape (e.g. colon and
lung) and aberrantly enlarged (e.g. colon, lung and prostate) or
dense (e.g. breast) nucleoli had distinctively higher ephrin-B2
staining. Dual staining on human colon cancer sample with both
anti-CD31 antibody and EC8 revealed some of the vasculatures
that were co-stained, indicative of EC8 detecting tumor-associated
vasculature (Fig. 4C).
Discussion
Ephrin-B2 is preferentially expressed in arterial endothelium
and smooth muscle cells, as well as neovasculature within the
tumor. Expression of ephrin-B2 is modulated by VEGF, smooth
muscle cell contact, and stress [25,26,27]. Ephrin-B2 has also
shown to be upregulated in many cancers, including colon [15],
uterine [16], ovarian [17] and esophageal cancers [18]. Despite
the importance of the role of ephrin-B2 in physiology and disease,
up until now monoclonal antibody specific to ephrin-B2 has not
been widely available. This may be attributed to the fact that
human ephrin-B2 is highly homologous to those of other
mammals including rodents, presenting a challenge to isolating
high affinity antibody from immunization and hybridoma
technique. Limited in vivo alternatives for making antibodies
against highly conserved antigens, including using mice with
impaired immune response [19,20], have been reported, yet the
concerns remain on the multi-specificity and low-affinity of auto-
antibodies [20].
Figure 3. Detection of ephrin-B2 expression in human cancer cell lines and tumor xenograft in mice. (A) Flow cytometry measurements
of EC8 binding to COLO205 and HCT116 cells (solid line) in comparison to the isotype control (shaded area). CHO cells with no ephrin-B2 expression
were also included for comparison. (B) RT-PCR detection of ephrin-B2 expression in different cell lines. (C) Immunostaining of ephrin-B2 on human
colon cancer xenografted in mice. Control denotes immunostaining without EC8 as a primary antibody. Tumor and stromal cells were indicated with
arrowhead and arrow, respectively. Circle indicates murine endothelium stained with EC8. Scale bar=20 mm.
doi:10.1371/journal.pone.0030680.g003
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ephrin-B2, which was selected from a phage library of human
single chain antibody. Rather than panning phage clones against
soluble antigens, we used yeast cells expressing antigens to pull
down reactive phage clones, which was found to be highly efficient
in rapidly enriching specific phage library. Given the library
diversity (10
8) and an enrichment factor of 10
2–10
3 per each round
of our screening strategy [21], we were able to observe specific
phage clones reactive to ephrin-B2 as early as after two rounds of
sorting. As antibody selection is based on monomeric interaction
between antigen-antibody, after conversion into a dimer by fusion
to IgG Fc, the affinity (KD=3.2 nM) of ephrin-B2 antibody (EC8)
was comparable to those of high affinity monoclonal antibodies
produced from hybridoma. Compared to many polyclonal
antibodies generated from peptide fragments by immunization,
EC8 selected against ephrin-B2 displayed in native conformation
on yeast surface was found to be conformation-specific and
discriminate ephrin-B2 from other ephrins with high homology.
Antibodies against EphB4 were found to inhibit tumor growth
and angiogenesis, some of which are being investigated for anti-
cancer therapy in preclinical studies [9,10]. Eph receptor antibodies
that were conjugated to small molecule drugs caused internalization
of drugs and inhibition of tumor growth in vivo [28,29]. Soluble
extracellulardomainofEphB4targeting ephrin-B2hasbeenused in
inhibiting angiogenesis and tumor growth in vivo [8]. We have
found that mAb EC8 potently antagonized ephrin-B2 binding to
EphB4, which would block forward and reverse signaling by EphB4
and ephrin-B2 interaction. Similar to the observation of EphB4
upregulation in some tumors, when human tissue array was probed
with mAb EC8, ephrin-B2 was found to be also overexpressed in
tumors in lung, breast, ovary, colon, and prostate over respective
normal tissue. Consistent with the previous observation of ephrin-
B2 expression in tumor-associated vasculature, EC8 delineated
ephrin-B2 expression in newly formed vessels within the tumor.
Upregulation of ephrin-B2 was also found in colorectal cancer cell
lines, COLO205 and HT108 both in cell culture and as a tumor
xenograft in mice. Notably, due to the cross-reactive nature of
antibody with murine ephrin-B2, mAb EC8 also identified tumor-
associated vasculature, simultaneously detecting ephrin-B2 in
human tumor as well as ephrin-B2 in murine host.
Neovasculatures in adults sprouting from arterial vessels and
capillaries, whether caused by VEGF-signaling, tissue injury, or
tumor growth, were found to express ephrin-B2. It is unknown
how ephrin-B2 upregulation in some of the tumors of epithelium
origin would perturb the balance between ephrin-B2 and Eph4
expressed in arterial and venous vessels, respectively, and
contribute to the tumor growth and metastasis. Given the
observation that overexpression of ephrin-B2 in some tumors is
correlated with poor prognosis [1,16], it will be an interesting
question if the role of ephrin-B2 together with EphB receptors in
some tumor is associated with the promotion of the vasculature
growth and the adenoma-carcinoma transition, facilitating tumor
metastasis. We propose that high affinity and antagonist antibodies
such as EC8 would provide a valuable tool for examining the role
of ephrin-B2 expression on tumor angiogenesis and migration.
Materials and Methods
Selection and expression of ephrin-B2-specific scFvs
A part of human ephrin-B2 ectodomain (Thr-22 to Gly-165)
was cloned into yeast surface display vector, CAga2 (a modified
Figure 4. Detection of ephrin-B2 expression in human tissue arrays. (A&B) Immunostaining of ephrin-B2 expression in human tumor tissue
arrays using EC8. Control denotes immunostaining without EC8 as a primary antibody. Tumor and stromal cells were indicated with arrowhead and
arrow, respectively. Scale bar=20 mm. PAC=Papillary Adenocarcinoma; AC=Adenocarcinoma; BR=Bronchus; AL=Alveoli; SC=Squamous Cell
Carcinoma; SAC=Serous Adenocarcinoma. IDC=Nonspecific Infiltrating Duct Carcinoma. (C) Immunofluorescence staining on human colon tumor
tissue demonstrating that EC8 (red) detects ephrin-B2 expressions in both cancer cells and tumor-associated vasculature (green). Blow up views of
the two areas indicated with dashed box are shown in the right panel. Scale bar=100 mm.
doi:10.1371/journal.pone.0030680.g004
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EBY100 by EZ-transformation kit (Zymo Research). Yeast culture
and protein induction were performed as previously described
[30]. Proteins displayed on yeast contain ephrin-B2 ectodomain,
Myc tag, and Aga2 from N- to C-terminal. Surface expression of
ephrin-B2 in yeast was measured by immunofluorescence flow
cytometry using mouse anti-Myc antibody (9E10, Santa Cruz
Biotechnology) followed by goat phycoerythrin-conjugated anti-
mouse antibody (Santa Cruz Biotechnology), as well as by
recombinant human EphB4-Fc chimera (Biomiga) followed by
goat phycoerythrin-conjugated anti-human antibody (Santa Cruz
Biotechnology). A phage library of human single chain variable
fragment (scFv) antibody with 10
8 diversity (Tomlinson I+J,
Source BioScience) was panned against ephrin-B2 expressing-yeast
cells, following a procedure previously described [21]. Briefly,
2610
13 phage clones were first incubated with phosphate buffered
saline (PBS) containing 2% nonfat dry milk (Carnation) for 30 min
at room temperature (RT), to which 2610
7 yeast cells expressing
unrelated protein (Zif268) was added for depletion of non-specific
phage binders. The mixture of phage and yeast cells were then
incubated for 1 h at RT with agitation. Non-binding phage clones
in the supernatant were removed after centrifugation to pellet
yeast cells, which were subsequently washed five times with PBS/
0.05%Tween 20. Then phage particles were eluted from yeast
cells with trypsin and used to infect Escherichia coli (TG1) to amplify
enriched phage library for the next round of selection. After three
rounds of selection, ,200 TG1 clones were picked to produce
individual phage clones. The binding of phage clones to ephrin-B2
expressing yeast cells was measured by immunofluorescence flow
cytometry using anti-His tag antibody (Sigma-Aldrich) followed by
goat phycoerythrin-conjugated anti-mouse antibody (Santa Cruz
Biotechnology).
Expression of scFv
Individual phage clones with high affinity binding to ephrin-B2
were sequenced, and selected scFv antibodies were solubly
expressed from bacteria HB2151 (Clontech). Transformed
HB2151 cells were grown at OD600=0.4, to which 1 mM
isopropyl b-D-1-thiogalactopyranoside was added. Cells were
induced to express protein at 25uC by culturing for 16 h with
shaking at 250 rpm. After induction, cells were spun down,
resuspended in binding buffer (50 mM sodium phosphate, pH 8.0,
300 mM sodium chloride, and 10 mM imidazole), sonicated to
break the cell wall, and were spun at 10,000 g for 15 min to
remove cell debris. Proteins in the supernatant were purified with
Ni-NTA column followed by gel filtration chromatography using
Superdex 75 column connected to AKTA Purifier (GE Health-
care). The purity and the size of proteins were confirmed by
sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE).
Cell culture
Chinese hamster ovary (CHO) cells [30] were maintained in
Ham’s F12 medium (Invitrogen) supplemented with 2 mM L-
glutamine and 5% fetal bovine serum (FBS). Colorectal adeno-
carcinoma COLO205 [31] were cultured in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 10% FBS and 1%
Penicillin-Streptomycin. HCT116 colon cancer cell line [32] was
grown in McCoy’s 5A Medium (Invitrogen) supplemented with
10% FBS. Human embryonic kidney (HEK) 293T cells [30] were
maintained in advanced DMEM supplemented with 10% FBS,
2 mM L-glutamine, 20 mg/mL hygromycin and 1% Penicillin-
Streptomycin. All cell cultures were maintained at 37uCi na
humidified 5% CO2 atmosphere. 293T cells stably expressing
ephrin-B2 were established by transfection of cells with pcDNA3.1
(Invitrogen) containing full-length ephrin-B2 with 200 mg/ml of
hygromycin for selection.
Immunofluorescence flow cytometry
Protein expression on yeast cell surface was analyzed by flow
cytometry as described [33]. Briefly, yeast cells were incubated
with primary antibodies (10 mg/ml) in 200 ml of labeling buffer
(PBS/0.5% bovine serum albumin) for 1 h with shaking at 30uC.
Cells were then washed and incubated with secondary antibodies
in 200 ml of labeling buffer for 1 h at RT. After washing, cells were
resuspended in 200 ml of labeling buffer and subjected to flow
cytometry. The expression of ephrin-B2 in mammalian cells was
detected by incubating cells with ephrin-B2 antibody for 1 h at
4uC, followed by Alexa Fluor 488 (AF488)-conjugated goat anti-
human secondary antibody (Invitrogen). Flow cytometry was
performed on a FACSCalibur (BD Biosciences) and analyzed with
CellQuest software (BD Biosciences).
Conversion of scFv into scFv-Fc
In order to fuse scFv into immunoglobulin G (IgG) constant
region (Fc) including a hinge sequence, scFv sequence followed by
IgG1 Fc was cloned into pcDNA3.1. scFv-Fc fusion protein was
expressed in 293T cells and purified with Protein A beads
(Thermo Scientific).
Conformation specificity and selectivity of EC8 against
ephrin-B2
Yeast cells expressing ephrin-B2 were incubated either in
50 mM Tris buffer (pH 8.0) containing 6 M guanidine hydro-
chloride for 20 min at room temperature, or in labeling buffer
(PBS/0.5% bovine serum albumin) heated to 80uC for 10 min, to
denature ephrin-B2. EC8 or EphB4-Fc binding to yeast cells after
denaturation of ephrin-B2 was then measured by flow cytometry.
To examine crossreactivity of EC8 to other ephrins, human
ephrin-B1 (Leu-24 to Gly-165) and ephrin-A5 (Pro-22 to Gly-169)
ectodomains were cloned and displayed on yeast surface.
Immunofluorescence flow cytometry was conducted with mouse
anti-Myc antibody (9E10, Santa Cruz Biotechnology), recombi-
nant human EphB2/Fc chimera (R&D Systems), and EC8
followed by respective secondary antibodies as previously
described.
Competition assay
Yeast cells expressing ephrin-B2 were incubated with varying
concentrations of mAb EC8 or affinity (protein A column, Pierce)
purified human IgG for 20 min at 30uC, to which recombinant
human EphB4 containing His-tag at C-terminal (R&D Systems)
was added at 100 nM and incubated for 20 min at 30uC. The
binding of EphB4 to yeast was detected by flow cytometry using
anti-His tag antibody, followed by phycoerythrin-conjugated goat
anti-mouse antibody.
Immunoprecipitation of ephrin-B2 by mAb EC8
293T cells with stable expression of ephrin-B2 were incubated
in lysis buffer (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10%
glycerol, 1% Triton X-100, 2 mM ethylenediaminetetraacetic acid
(EDTA), protease inhibitor cocktail (Sigma)) for 30 min on ice.
Cell debris were removed by centrifugation for 20 min at
14,000 g. Total protein lysate was precleared by Protein A beads
for 1 h at 4uC. After centrifugation, supernatants were collected
and incubated with 10 mg/ml EC8 for 2 h at 4uC, followed by
incubation with Protein A beads overnight at 4uC. Immunopre-
Conformation-Specific mAb against Ephrin-B2
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30680cipitated proteins were run on SDS-polyacrylamide gel and
transferred to polyvinyl difluoride membranes (Bio-Rad) for
western blot analysis. The membrane was first blocked with 5%
non-fat milk in TBS/0.05%Tween 20 for 1 h at RT, incubated
with rabbit polyclonal anti-ephrin-B2 antibody (Genscript) over-
night at 4uC, and detected by horseradish peroxidase (HRP)-
conjugated anti-rabbit antibody (Santa Cruz). ECL substrate
(Pierce) was added to the membrane for 1 min at RT, which was
exposed to X-ray film.
Immunofluorescence microscopy for ephrin-B2 labeling
and internalization by EC8
Antibody labeling of ephrin-B2 was examined separately for
cell-surface vs. internalized pool of ephrin-B2. 293T cells were
grown on culture slides (BD Biosciences) to 50% confluence, to
which 10 mg/ml of anti-ephrin-B2 antibody (EC8) was added.
Cells were then incubated for 1 h at 37uC to allow antibody
binding and endocytosis to occur. To detect EC8 bound to cell
surface ephrin-B2, cells were fixed with 4% formaldehyde in PBS
for 20 min at RT and incubated with blocking solution (PBS with
5% goat serum) for 1 h, followed by incubation with fluorescein-
conjugated goat anti-human antibody (Invitrogen). Then to label
internalized EC8, cells were permeabilized by 100% ice-cold
methanol for 15 min on ice and incubated with blocking solution
for 30 min at RT, followed by incubation with rhodamine-
conjugated anti-human antibody (Invitrogen). Cell surface vs.
internalized antibodies were imaged by confocal microscope (Zeiss
LSM 710).
RT-PCR
Total RNA was isolated from cultured cells with RNAeasy kit
(Qiagen, Valencia, CA) according to the manufacturer’s protocol.
1 mg of total RNA was used for reverse transcription. The
expression of GAPDH and ephrin-B2 was analyzed with the
following primers: GAPDH: 59-TTGAGGTCAATGAAGGGG-
TC/59-GAAGGTGAAGGTCGGAGTCA; Ephrin-B2: 59-GTG-
TGGAAGTACTGCTGGGGTGTT/59-GGCACAGTTGAGG-
AGAGGGGTATT.
Immunohistology of tumor xenograft
10
6 human colon cancer cells (COLO205 and HCT116; a kind
gift from Dr. Michael King, Cornell University) were mixed in
0.1 ml 50% Matrigel (BD) and xenografted into nude mice
(Jackson Laboratory). 14 days after injection when xenograft
tumor size reached ,80 mm
3, mice were euthanized and tumors
were harvested. All animal experiments were conducted in
compliance with the regulations defined by the Institutional
Laboratory Animal Use and Care Committee of Cornell
University (Protocol number 2009-0071). Harvested tumors were
fixed in 4% paraformaldehyde overnight at RT, rinsed 3 times for
10 min at RT each in 30% ethanol and then 50% ethanol, and
then kept in 70% ethanol for several hours before embedding into
a paraffin block for sectioning. In order to detect ephrin-B2 in the
xenograft sections, tissues sections were deparaffinized in xylene 3
times for 4 min each at RT, rehydrated with graded ethanol, and
then boiled in 10 mM citrate buffer (pH 6.0) for 10 min for
antigen retrieval. The tissue sections were blocked with blocking
solution (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM KCl,
0.3% Triton X-100, 1% goat serum) for 1 h at RT. Sections were
incubated with the primary antibodies at 1 mg/ml overnight at
4uC, followed by incubation with secondary biotin-conjugated
goat anti-human antibody (Invitrogen). Endogenous peroxidase
activity was quenched with 0.3% hydrogen peroxide in methanol
for 10 minutes at RT. Peroxidase-conjugated streptavidin (Vec-
tastain Elite ABC stain, Vector Laboratories) was added to the
sections. After each incubation, sections were washed 3 times with
TBS buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 2 mM KCl).
Sections were then exposed to chromogen diaminobenzidine
peroxidase substrate (Invitrogen) for 5 min, rinsed with water, and
counterstained with Mayer’s hematoxylin, dehydrated in graded
ethanol, and cleared in xylene. Slides were sealed in mounting
medium and a coverslip. Negative control slides were treated same
way except for the use of primary antibody.
Immunohistology of human tissue array
Human tumor tissue array (TP484, US Biomax) was depar-
affinized and subjected to the same procedures as used for the
immunostaining of tumor xenograft with EC8. Selected tumor
tissue array slides were also used for immunofluorescence. After
antigen retrieval and blocking, sections were incubated with
primary antibodies (EC8, mouse anti-human CD31 antibody
(Invitrogen)) at 1 mg/ml overnight at 4uC. After washing, tissue
sections were incubated with AF488-conjugated goat anti-mouse
secondary antibody, biotin-conjugated goat anti-human antibody,
and were subsequently labeled with rhodamine-conjugated
streptavidin. After each incubation, sections were washed 3 times
with TBS buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 2 mM
KCl). Immunofluorescent images were acquired with a fluorescent
microscope (MetaMorph, Molecular Devices).
Statistical analysis
Data were expressed as mean 6 standard deviation of no
smaller than triplicates, and analyzed for statistical significance
using GraphPad Prism 5 (Graphpad Software). Student’s t-test was
used to compare the binding levels and to determine statistical
significance (Fig. 2D).
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